Why I think this fallen FTSE 100 stock is a great value growth buy

This FTSE 100 (INDEXFTSE: UKX) growth stock was a high-flying star until it went into a nosedive. But now I reckon the shares are good value.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

NMC Health (LSE: NMC) was once a bit of a FTSE 100 growth darling, climbing by a massive 1,100% in the five years to August 2018.

But the slide that’s cut in since then shows that overheating growth stories aren’t restricted to the smaller-cap indices, and they can happen to top-index stocks too. We’ve now seen NMC shares lose 43% of their value since that peak, and the stock was one of Tuesday’s biggest morning fallers with a 4% drop.

But these share price movements on their own are fairly meaningless, and we need to put them in some sort of valuation context. Back in 2017 when NMC, a major healthcare provider based in the United Arab Emirates, was a big investors’ favourite, the shares ended the year on a trailing P/E multiple 37.6.

Valuation

That was high even by small-cap growth stock standards. But now the share price has fallen back so much, as so often happens when prospects for a growth stock retreat from brilliant to merely very good, there’s a forward P/E of 21 for the current year, dropping to just 17 based on 2020 forecasts.

Before the share price slump, NMC was recording solid annual growth, and that’s still forecast to continue with an EPS hike of 13% on the cards for this year and a further 28% pencilled in for 2020. And we’re looking at a 2020 PEG ratio of 0.6, which is a strong growth indicator that’s rarely seen at that level for a FTSE 100 stock.

I see no risks for the current year, with the company having told us at the interim stage that it’s primed to meet full-year expectations, as it recorded EBITDA of $323.5m (post IFRS 16), with the pre-IFRS16 equivalent up 22.5% at $276.3m.

Debt

One major issue, as with so many growth companies in their expansion stage, is debt. NMC’s stands at a net debt-to-EBITDA ratio of 3.4 times, now that the company has adopted IFRS 16. A meaningful prior comparison isn’t possible on that score, but the pre-IFRS 16 equivalent of 2.7 times represents a significant drop from the 3.4 times multiple a year previously.

Though I’m usually very wary when I see high net debt as a proportion of earnings, it’s mostly a problem for mature companies when they’re saddled with so much debt that their earnings can’t make much of an annual dent in it. But NMC is not remotely in that condition, and a company with very strong growth prospects having funded a lot of its expansion with debt is not necessarily a cause for concern — provided the cash flow is there and growing.

Flowing

In the case of NMC, despite earlier fears, cash flow is moving in the right direction. The firm recorded one of its highest EBITDA-to-free cash flow conversion rates in the half, and is significantly improving its cash flow metrics. The firm’s working capital cycle reduced to 90 days (from 106 days), receivable days dropped to 89 (from 99) and inventory days fell to 56 (from 74).

The healthcare market in the Middle East is still a relatively fledgling one, and I think NMC Health has used its early-mover advantage extremely well in a way that many fail to achieve. Liquidity is improving, I think management is top class, and I see a Buy now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How much would I need to invest in income shares to earn £300 a month?

What kind of lump sum would be required to earn £300 a month by taking advantage of some of the…

Read more »

Investing For Beginners

Up 31% in a month, could this FTSE 250 stock be getting bought out?

Jon Smith takes a look at speculation that's pushing the share price of a FTSE 250 share higher and considers…

Read more »

Investing Articles

Here’s how I’d follow Warren Buffett to start building passive income in 2025

Ben McPoland highlights one FTSE 250 firm with a strong competitive edge that he thinks can continue rewarding investors with…

Read more »

Investing Articles

Burberry shares: undervalued FTSE gems that are ready to rocket?

Burberry shares soared at the beginning of the week as the takeover rumour mill went into overdrive. Is Paul Summers…

Read more »

US Stock

Here are the latest share price forecasts for S&P 500 giant Amazon

Amazon has generated monster gains for investors over the last decade. And Wall Street analysts believe the S&P 500 stock…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »